AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Immix Biopharma shares surge 30.04% premarket after NXC-201 Phase 2 trial shows 75% complete response rate in AL amyloidosis.
ByAinvest
Monday, Dec 8, 2025 4:18 am ET1min read
Immix Biopharma surged 30.04% in premarket trading following the release of robust Phase 2 clinical trial results for its CAR-T therapy NXC-201 in relapsed/refractory AL Amyloidosis. The therapy demonstrated a 75% complete response rate (15/20 patients) and MRD negativity in four of five pending cases, suggesting a potential future 95% CR rate. These results, presented at ASH 2025, highlight NXC-201’s potential to address a high-unmet-need market, with a planned 2026 Biologics License Application. Additionally, the company announced a $100 million equity offering to fund NXC-201 development, further signaling confidence in the program’s regulatory and commercial trajectory. The data’s strength and the BLA timeline likely drove immediate investor optimism.
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet